founders. A whole range of unique analytical and data processing developments have been achieved, and these, together with an unparalleled set of application areas, underpin a continuing substantial lead in the field.

Metabonomics characterises the key biochemical changes caused by a range of interventions and conditions, such as drug toxicity in animals and man, the diagnosis and course of clinical disease, the effects of therapeutic intervention and the impact of nutrition and life-style changes. The approach has the potential to impact strongly on drug discovery and development from lead molecule selection to marketing of clinically successful drugs. Metabometrix has successfully completed projects across this wide range of biomedical applications for both industrial and academic clients.

In addition to its own intrinsic power, metabonomics is a key driver for integrating knowledge at all of the levels of molecular biology to provide a true top-down systems biology understanding, and Metabometrix, with its in-house expertise, is well placed to exploit this unique advantage.

Our headquarters is conveniently located in central London in the state-of- the-art Imperial Incubator on the Imperial College London, South Kensington campus. We also have modern, advanced analytical technology and sophisticated data processing and statistics tools for generating data and providing interpretation.

Metabometrix works with a large range of clients in the pharmaceutical, biotechnology and life science industries. The principal collaborative research areas are in predictive toxicology, disease biomarkers and patient profiling, better clinical trial targeting, and assessment of disease risk based on epidemiological cohorts.

In additional to studies for commercial clients and contracts for government organisations, Metabometrix has recently been the leading private sector participant in two large EC-funded consortia.